Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

NCT07225816 · Recruiting

Last updated 2026-05-28

This clinical trial is examining how different fasting durations and temporary pauses in GLP-1 medications (liraglutide or semaglutide) affect stomach emptying in adults with obesity who are taking these medications.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 75 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-11 · est. completion 2026-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07225816 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.

Treatments tested

Liraglutide Drug

Participants will receive liraglutide subcutaneously.
Oral Semaglutide Drug

Participants will receive semaglutide orally.
Semaglutide Drug

Participants will receive semaglutide subcutaneously.

Main thing measured	Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	semaglutide, liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07225816 ↗